Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10810	Companies
234087	Keywords
162845	Articles
125094	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 04/18/2024 at 07:00, 2 years 3 months ago

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
Biophytis forms new Scientific Advisory Board for phase 2 OBA clinical study in obesity, including Professor Dennis Villareal and Professor Francisco Guarner. IND filing with FDA imminent

Biophytis Scientific Advisory Board Obesity Phase 2 OBA Clinical Study IND Filing
BRIEF

published on 04/15/2024 at 07:05, 2 years 3 months ago

Biophytis Enhances Intellectual Property in Obesity Treatment with New Patent Application

Biophytis Pharmaceuticals Patent Application BIO101 Obesity
REGULATED PRESS RELEASE

published on 04/15/2024 at 07:00, 2 years 3 months ago

Biophytis files a patent application and strengthens its intellectual property in obesity
Biophytis files a patent application to strengthen its intellectual property in obesity. The new patent extends BIO101's exclusivity period in treating obesity, positioning Biophytis in a fast-growing market

Biophytis Intellectual Property Clinical Trial Patent Application Obesity
BRIEF

published on 04/08/2024 at 23:17, 2 years 3 months ago

Biophytis Reports 2023 Financial Results and Business Updates

Biophytis Financial Results 2023 Sarcopenia BIO101 COVID-19 Treatment
BRIEF

published on 04/08/2024 at 23:15, 2 years 3 months ago

Biophytis Initiates Phase 2 Clinical Study for Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 GLP-1 Receptor Agonists OBA Phase 2 Study
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 2 years 3 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 2 years 3 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
BRIEF

published on 04/08/2024 at 23:09, 2 years 3 months ago

Biophytis announces its 2023 financial results and provides an update on its activities

Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF

published on 04/08/2024 at 23:05, 2 years 3 months ago

Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 3 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial

Accesswire

Published on 08/06/2026 at 15:00, 6 hours 9 minutes ago

Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 14:30, 6 hours 39 minutes ago

Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook
Published on 08/06/2026 at 14:30, 6 hours 39 minutes ago

NV Gold Announces Expansion of Holdings and Drill Program at the Slumber Gold Project in Nevada
Published on 08/06/2026 at 14:30, 6 hours 39 minutes ago

AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
Published on 08/06/2026 at 14:00, 7 hours 9 minutes ago

Adcore to Publish Second Quarter 2026 Results on August 13, 2026

View all ACCESSWIRE

EQS Group

Published on 08/06/2026 at 19:05, 2 hours 4 minutes ago

Cision Wins 2026 MarTech Breakthrough Awards for Social Listening, Press Release Distribution, and AEO
Published on 08/06/2026 at 18:24, 2 hours 44 minutes ago

EQS-Adhoc: Allgeier SE: Allgeier Increases Revenue by 10 Percent in the First Half of 2026 and Confirms Its Guidance for 2026
Published on 08/06/2026 at 17:34, 3 hours 35 minutes ago

Issue of Equity
Published on 08/06/2026 at 17:20, 3 hours 49 minutes ago

Strutt Enters Europe: Expands Product Lineup with New ev¹e Variant and Showcases Evolving Smart Ecosystem at IFA 2026
Published on 08/06/2026 at 16:15, 4 hours 54 minutes ago

Monotype and Kittl Expand Partnership To Bring Brand Typography Directly Into Creative Workflows

Les Echos

Published on 08/06/2026 at 18:26, 2 hours 43 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 17:45, 3 hours 24 minutes ago

Declaration of voting rights at the end of July 2026
Published on 08/06/2026 at 17:45, 3 hours 24 minutes ago

July 2026
Published on 08/06/2026 at 17:35, 3 hours 34 minutes ago

Groupe des Assurances du Crédit Mutuel (GACM)’s Solvency II ratio was 227% as of June 30, 2026
Published on 08/06/2026 at 17:35, 3 hours 34 minutes ago

Availability of the financial statements of Groupe des Assurances du Crédit Mutuel for the first half of 2026

View all LES ECHOS COMFI WIRE